- Home
- ATHA vs BLRX Comparison
ATHA vs BLRX Comparison
Compare ATHA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- BLRX
- Stock Information
- Founded
- ATHA 2011
- BLRX 2003
- Country
- ATHA United States
- BLRX Israel
- Employees
- ATHA N/A
- BLRX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- BLRX Health Care
- Exchange
- ATHA Nasdaq
- BLRX Nasdaq
- Market Cap
- ATHA 21.0M
- BLRX 17.3M
- IPO Year
- ATHA 2020
- BLRX 2011
- Fundamental
- Price
- ATHA $0.43
- BLRX $3.59
- Analyst Decision
- ATHA Buy
- BLRX Strong Buy
- Analyst Count
- ATHA 4
- BLRX 2
- Target Price
- ATHA $11.25
- BLRX $220.00
- AVG Volume (30 Days)
- ATHA 210.5K
- BLRX 154.8K
- Earning Date
- ATHA 03-04-2025
- BLRX 03-25-2025
- Dividend Yield
- ATHA N/A
- BLRX N/A
- EPS Growth
- ATHA N/A
- BLRX N/A
- EPS
- ATHA N/A
- BLRX N/A
- Revenue
- ATHA N/A
- BLRX $21,991,000.00
- Revenue This Year
- ATHA N/A
- BLRX N/A
- Revenue Next Year
- ATHA N/A
- BLRX N/A
- P/E Ratio
- ATHA N/A
- BLRX N/A
- Revenue Growth
- ATHA N/A
- BLRX N/A
- 52 Week Low
- ATHA $0.41
- BLRX $3.20
- 52 Week High
- ATHA $4.21
- BLRX $57.60
- Technical
- Relative Strength Index (RSI)
- ATHA 34.62
- BLRX 36.94
- Support Level
- ATHA $0.42
- BLRX $3.26
- Resistance Level
- ATHA $0.46
- BLRX $4.17
- Average True Range (ATR)
- ATHA 0.04
- BLRX 0.28
- MACD
- ATHA -0.00
- BLRX 0.24
- Stochastic Oscillator
- ATHA 10.85
- BLRX 36.26
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.